Title: Engineering a next-generation glycoconjugate-like Streptococcus pneumoniae vaccine

Authors: Andrew B. Hill^{1,2}, Marie Beitelshees^{1,2}, Roozbeh Nayerhoda³, Blaine A. Pfeifer^{2,3*}, Charles H. Jones^{1*}

Affiliations:

¹Abcombi Biosciences Inc., 1576 Sweet Home Road, Amherst, New York, 14228, USA.

²Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, New York, 14260, USA.

³Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, New York, 14260, USA.

*Correspondence to: charles.jones@abcombibio.com, blainepf@buffalo.edu.

Pages S1-S14

Tables 1-8

Figures 1-3

Supplementary Table 1: Microfloral bacteria with GlpO homologs tested for cross-reactivity with percent homology of protein regions indicated

| | | Average Homology | | |
|-----------------------------|--|------------------|--------------------|---------|
| Species | Colonization Location | Full-Length | Surface-Accessible | Epitope |
| Streptococcus mitis* | Oral Cavity, Throat, Nasopharynx | 98% | 92% | 99% |
| Streptococcus oralis | Oral Cavity | 97% | 97% | 99% |
| Streptococcus infantis* | Upper Respiratory | 97% | 97% | 97% |
| Streptococcus cristatus | Oral Cavity | 95% | 95% | 95% |
| Streptococcus parasanguinis | Oral Cavity | 93% | 92% | 95% |
| Streptococcus sanguinis | Oral Cavity | 94% | 94% | 95% |
| Streptococcus gordonii | Oral Cavity | 95% | 94% | 94% |
| Streptococcus salivarius | Oral Cavity, Upper Respiratory | 94% | 94% | 93% |
| Streptococcus dysgalactiae* | Gastrointestinal and Genitourinary Tract | 75% | 75% | 73% |
| Streptococcus pyogenes | Upper Respiratory, Skin | 75% | 74% | 72% |
| Lactobacillus iners | Vaginal Tract | 63% | 64% | 70% |
| Streptococcus agalactiae** | Gastrointestinal and Genitourinary Tract | 71% | 72% | 68% |
| Alloiococcus otitis* | Nasopharynx | 64% | 64% | 64% |
| Enterococcus durans | Gastrointestinal Tract | 61% | 61% | 64% |
| Lactobacillus plantarum** | Gastrointestinal Tract | 62% | 63% | 62% |
| Enterococcus faecalis* | Gastrointestinal Tract | 63% | 63% | 62% |
| Lactobacillus salivarius** | Gastrointestinal Tract | 60% | 59% | 61% |
| Aerococcus christensenii* | Vaginal Tract | 60% | 62% | 61% |
| Pediococcus acidilactici** | Gastrointestinal Tract | 58% | 58% | 58% |
| Lactobacillus pentosus | Vaginal Tract, Gastrointestinal Tract | 63% | 62% | 58% |

^{*}Evaluated for antibody binding via immunofluorescence assay
**Evaluated for antibody binding and neutralization activity using OPA assay

Supplementary Table 2: Complete OPA data for LEPS(20V):PncO dose escalation

| Serotype | PC\ | /13 | PPSV | /23 | LEPS(20 (34 | | LEPS(20) (68 | | LEPS(20\ (136 | /):PncO µg) |
|----------|------------|-----|------------|-----|----------------|-----|-----------------|-----|------------------|----------------|
| | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR |
| 1 | 150 | | 126 | | 120 | 45 | 205 | 150 | 189 | 128 |
| 2 | | | 101 | | 110 | 145 | 136 | 150 | 172 | 208 |
| 3 | 120 | | 30 | | 112 | 182 | 136 | 196 | 132 | 230 |
| 4 | 48 | | 51 | | 182 | 486 | 233 | 192 | 224 | 571 |
| 5 | 56 | | 92 | | 53 | 366 | 73 | 608 | 62 | 545 |
| 6A | 59 | | | | 211 | 88 | 285 | 491 | 257 | 111 |
| 6B | 50 | | 30 | | 178 | 18 | 235 | 96 | 207 | 30 |
| 6C | | | | | | 317 | | 23 | | 358 |
| 6D | | | | | | 440 | | 289 | | 489 |
| 7A | | | | | | 162 | | 489 | | 231 |
| 7B | | | | | | 94 | | 174 | | 120 |
| 7C | | | | | | 152 | | 115 | | 188 |
| 7F | 180 | | 33 | | 171 | 44 | 234 | 172 | 227 | 72 |
| 8 | | | 81 | | 135 | 70 | 168 | 56 | 198 | 81 |
| 9A | | | | | | 100 | | 67 | | 117 |
| 9N | | | 59 | | 20 | 397 | 24 | 117 | 27 | 529 |
| 9V | 187 | | 125 | | 149 | 435 | 165 | 468 | 193 | 435 |
| 10A | | | 150 | | | 47 | | 392 | | 83 |
| 10F | | | | | | 30 | | 62 | | 44 |
| 11A | | | 96 | | | 59 | | 40 | : | 76 |
| 11B | | | | | | 66 | | 63 | | 110 |
| 11C | | | : | | | 82 | | 86 | | 96 |
| 12A | | | | | | 102 | | 86 | | 108 |
| 12B | | | | | | 354 | | 95 | | 450 |
| 12F | | | 38 | | 161 | 366 | 190 | 429 | 221 | 515 |
| 13 | | | | | | 126 | | 472 | | 158 |
| 14 | 105 | | 37 | | 51 | 221 | 63 | 122 | 58 | 230 |
| 15A | | | ! | | | 61 | | 234 | : | 88 |
| 15B | | | 172 | | | 386 | | 80 | : | 382 |
| 15C | | | | | | 306 | | 375 | | 485 |
| 15F | | | | | | 196 | | 401 | | 305 |
| 16A | | | | | | 182 | | 229 | | 295 |
| 16F | | | | | | 230 | | 246 | | 311 |

| 17A | | <u></u> | | : | | 283 | | 251 | | 312 |
|-----|-----|-------------|-----|-------------|-----|-----|-----|-----|-----|-----|
| 17F | | | 110 | | 126 | 229 | 139 | 260 | 125 | 345 |
| 18A | | | | | | 133 | | 264 | | 163 |
| 18B | | | | | | 303 | | 163 | | 379 |
| 18C | 180 | | 48 | | 212 | 393 | 282 | 333 | 245 | 612 |
| 18F | | | | | | 173 | | 523 | | 198 |
| 19A | 180 | | 134 | | 180 | 76 | 243 | 185 | 224 | 96 |
| 19C | | | | | | 172 | | 75 | | 267 |
| 19F | 200 | | 55 | | 326 | 322 | 365 | 217 | 325 | 519 |
| 20 | | | 43 | | 102 | 201 | 122 | 425 | 122 | 245 |
| 21 | | | | | | 322 | | 211 | | 490 |
| 22A | | | | | | 406 | | 412 | | 655 |
| 22F | | | 79 | | 201 | 432 | 272 | 504 | 253 | 545 |
| 23A | | | | | | 72 | | 510 | | 70 |
| 23B | | ! | | | | 353 | | 66 | | 615 |
| 23F | 170 | | 15 | | 81 | 333 | 97 | 455 | 106 | 365 |
| 24A | | | | ! | | 23 | | 376 | | 22 |
| 24B | | | | | | 284 | | 21 | | 256 |
| 24F | | | | | | 80 | | 272 | | 96 |
| 25F | | | | | | 269 | | 100 | | 328 |
| 27 | | | | | | 108 | | 288 | | 151 |
| 28A | | | | | | 214 | | 141 | | 193 |
| 28F | | <u></u> | | <u></u> | | 358 | | 197 | | 470 |
| 29 | | | | | | 82 | | 351 | | 121 |
| 30 | | | | | | 274 | | 96 | | 325 |
| 31 | | | | | | 199 | | 346 | | 240 |
| 33A | | | | | | 401 | | 261 | | 430 |
| 33F | | | 20 | | | 199 | | 361 | | 241 |
| 34 | | | | i | | 320 | | 217 | | 414 |
| 35A | | | | | | 109 | | 324 | | 118 |
| 35B | | i ! ! | | i ! ! | | 61 | | 109 | | 100 |
| 35C | | | | ! | | 212 | | 80 | | 304 |
| 35F | | | | | | 32 | | 240 | | 42 |
| 37 | | | | | | 161 | | 42 | | 211 |
| 38 | | | | | | 92 | | 187 | | 118 |
| 39 | | | | | | 231 | | 109 | | 266 |
| 41A | | | | | | 320 | | 274 | | 415 |
| 42F | | | | | | 188 | | 349 | | 279 |

Supplementary Table 3: Complete OPA data for LEPS(20V):GIpO+PncO dose escalation

| Serotype | PC\ | PCV13 PPSV23 LEPS(20V):GlpO+PncO LEPS(20V):GlpO (68 μg) (136 μg) | | PPSV23 | | | g) (272 µg) | | | |
|----------|------------|--|------------|--------|------------|-----|-------------|-----|------------|-----|
| | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR | Planktonic | BFR |
| 1 | 150 | | 126 | | 176 | 45 | 219 | 150 | 146 | 128 |
| 2 | | | 101 | | 110 | 145 | 212 | 150 | 143 | 208 |
| 3 | 120 | | 30 | | 144 | 182 | 143 | 196 | 184 | 230 |
| 4 | 48 | | 51 | | 222 | 486 | 233 | 192 | 191 | 571 |
| 5 | 56 | | 92 | | 63 | 366 | 52 | 608 | 63 | 545 |
| 6A | 59 | | | | 302 | 88 | 287 | 491 | 269 | 111 |
| 6B | 50 | | 30 | | 289 | 18 | 263 | 96 | 347 | 30 |
| 6C | | | : | | | 317 | | 23 | | 358 |
| 6D | | | | | | 440 | | 289 | | 489 |
| 7A | | | | | | 162 | | 489 | | 231 |
| 7B | | | | | | 94 | | 174 | | 120 |
| 7C | | | | | | 152 | | 115 | | 188 |
| 7F | 180 | | 33 | | 245 | 44 | 247 | 172 | 196 | 72 |
| 8 | | | 81 | | 154 | 70 | 178 | 56 | 171 | 81 |
| 9A | | | | | | 100 | | 67 | | 117 |
| 9N | | | 59 | | 28 | 397 | 23 | 117 | 26 | 529 |
| 9V | 187 | | 125 | | 208 | 435 | 189 | 468 | 181 | 435 |
| 10A | | | 150 | | | 47 | | 392 | | 83 |
| 10F | | | | | | 30 | | 62 | | 44 |
| 11A | : | | 96 | | | 59 | | 40 | | 76 |
| 11B | | | | | | 66 | | 63 | | 110 |
| 11C | | | | | | 82 | | 86 | | 96 |
| 12A | | | ; | | | 102 | | 86 | | 108 |
| 12B | | | : | | | 354 | | 95 | | 450 |
| 12F | | | 38 | | 225 | 366 | 241 | 429 | 247 | 515 |
| 13 | | | | | | 126 | | 472 | | 158 |
| 14 | 105 | | 37 | | 57 | 221 | 100 | 122 | 157 | 230 |
| 15A | : | | : | | | 61 | | 234 | | 88 |
| 15B | | | 172 | | | 386 | | 80 | | 382 |
| 15C | | | ! | | | 306 | | 375 | | 485 |
| 15F | | | | | | 196 | | 401 | | 305 |
| 16A | | | | | | 182 | | 229 | | 295 |
| 16F | | | | | | 230 | | 246 | | 311 |

| 474 | | ! | l | ! | l | | | 054 | | 240 |
|-----|-----|-------------|-----|--------------|-----|-----|-----|-----|-----|-----|
| 17A | | | | | 400 | 283 | | 251 | | 312 |
| 17F | | | 110 | | 168 | 229 | 111 | 260 | 208 | 345 |
| 18A | | | | | | 133 | | 264 | | 163 |
| 18B | | | | | | 303 | | 163 | | 379 |
| 18C | 180 | | 48 | | 260 | 393 | 216 | 333 | 278 | 612 |
| 18F | | | | | | 173 | | 523 | | 198 |
| 19A | 180 | | 134 | | 216 | 76 | 190 | 185 | 182 | 96 |
| 19C | | | | | | 172 | | 75 | | 267 |
| 19F | 200 | ! | 55 | | 372 | 322 | 273 | 217 | 420 | 519 |
| 20 | | | 43 | | 129 | 201 | 103 | 425 | 123 | 245 |
| 21 | | | | | | 322 | | 211 | | 490 |
| 22A | | | | | | 406 | | 412 | | 655 |
| 22F | | <u></u> | 79 | <u> </u> | 285 | 432 | 258 | 504 | 285 | 545 |
| 23A | | | | <u>;</u> | | 72 | | 510 | | 70 |
| 23B | | <u></u> | | <u> </u> | | 353 | | 66 | | 615 |
| 23F | 170 | | 15 | | 115 | 333 | 125 | 455 | 138 | 365 |
| 24A | | <u></u> | | <u></u> | | 23 | | 376 | | 22 |
| 24B | | | | | | 284 | | 21 | | 256 |
| 24F | | | | | | 80 | | 272 | | 96 |
| 25F | | | | | | 269 | | 100 | | 328 |
| 27 | | | | | | 108 | | 288 | | 151 |
| 28A | | | | | | 214 | | 141 | | 193 |
| 28F | | i ! | | | | 358 | | 197 | | 470 |
| 29 | | | | | | 82 | | 351 | | 121 |
| 30 | | | | | | 274 | | 96 | | 325 |
| 31 | | | | | | 199 | | 346 | | 240 |
| 33A | | | | | | 401 | | 261 | | 430 |
| 33F | | | 20 | | | 199 | | 361 | | 241 |
| 34 | | | | | | 320 | | 217 | | 414 |
| 35A | | | | | | 109 | | 324 | | 118 |
| 35B | | | | | | 61 | | 109 | | 100 |
| 35C | | | | | | 212 | | 80 | | 304 |
| 35F | | | | | | 32 | | 240 | | 42 |
| 37 | | | | | | 161 | | 42 | | 211 |
| 38 | | | | | | 92 | | 187 | | 118 |
| 39 | | | | | | 231 | | 109 | | 266 |
| 41A | | | | | | 320 | | 274 | | 415 |
| 42F | | | | | | 188 | | 349 | | 279 |
| | | | | | | • | | | | |

Supplementary Table 4: LEPS(24V):PncO planktonic serotype OPA data

| Serotype | PCV13 | PPSV23 | LEPS(24V):CRM197 | LEPS(24V):PncO |
|----------|-------|--------|------------------|----------------|
| 1 | 150 | 126 | 156 | 178 |
| 2 | | 101 | 129 | 134 |
| 3 | 120 | 30 | 110 | 113 |
| 4 | 48 | 51 | 211 | 209 |
| 5 | 56 | 92 | 105 | 210 |
| 6A | 59 | | 254 | 312 |
| 6B | 50 | 30 | 217 | 217 |
| 7F | 180 | 33 | 169 | 186 |
| 8 | | 81 | 147 | 181 |
| 9N | | 59 | 88 | 108 |
| 9V | 187 | 125 | 165 | 148 |
| 10A | | 150 | 178 | 196 |
| 11A | | 96 | 205 | 205 |
| 12F | | 38 | 179 | 186 |
| 14 | 105 | 37 | 165 | 172 |
| 15B | | 172 | 146 | 146 |
| 17F | | 110 | 155 | 154 |
| 18C | 180 | 48 | 257 | 272 |
| 19A | 180 | 134 | 211 | 232 |
| 19F | 200 | 55 | 210 | 189 |
| 20 | | 43 | 114 | 139 |
| 22F | | 79 | 255 | 232 |
| 23F | 170 | 15 | 182 | 189 |
| 33F | | 20 | 205 | 262 |

Supplementary Table 5: Size and charge characterization of LEPS variants

| Attachment Strategy | Size (nm) | Zeta Potential (mV) |
|---------------------|------------------|---------------------|
| [Ni-NTA] | | |
| Empty | 110.0 ± 17.6 | -11.0 ± 1.4 |
| 20-Valent | 193.5 ± 13.8 | -10.2 ± 2.8 |
| 20-Valent + Protein | 179.2 ± 20.6 | -17.9 ± 2.2 |
| 24-Valent | 249.1 ± 9.0 | -12.3 ± 1.6 |
| 24-Valent + Protein | 286.7 ± 20.2 | -15.9 ± 2.7 |
| [Co-NTA] | | |
| Empty | 113.3 ± 22.5 | -9.8 ± 1.7 |
| 20-Valent | 181.9 ± 14.2 | -11.8 ± 3.2 |
| 20-Valent + Protein | 225.8 ± 16.5 | -17.5 ± 2.4 |
| 24-Valent | 221.3 ± 10.8 | -11.8 ± 1.6 |
| 24-Valent + Protein | 237.9 ± 17.8 | -13.5 ± 3.4 |
| BSB | | |
| Empty | 128.5 ± 14.2 | -13.7 ± 2.3 |
| 20-Valent | 249.2 ± 18.9 | -16.4 ± 2.0 |
| 20-Valent + Protein | 207.1 ± 19.7 | -23.1 ± 2.7 |
| 24-Valent | 255.3 ± 13.6 | -16.4 ± 1.9 |
| 24-Valent + Protein | 275.4 ± 21.9 | -22.2 ± 1.8 |
| BS | | |
| Empty | 138.0 ± 16.3 | -15.5 ± 2.6 |
| 20-Valent | 225.3 ± 11.6 | -14.1 ± 2.0 |
| 20-Valent + Protein | 232.5 ± 19.2 | -20.5 ± 1.4 |
| 24-Valent | 256.3 ± 16.0 | -16.6 ± 2.4 |
| 24-Valent + Protein | 265.1 ± 15.5 | -22.0 ± 1.2 |

Supplementary Table 6: Body and organ weight of mice post vaccination


| Animal | Sham | | | Alum:PncO | | LE | PS(20V):CRM1 | 97 |
|--------------------|----------------|------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Terminal Weight | - | | 1× | 5× | 10× | 1× | 5× | 10× |
| | | Male CD-1 Mice (N=5) | | | | | | |
| Body Weight (g) | 30.3 ± 3.1 | | 30.6 ± 2.1 | 29.7 ± 2.3 | 31.8 ± 2.4 | 31.5 ± 2.9 | 30.3 ± 1.8 | 31.5 ± 2.5 |
| Brain Weight (mg) | 472.0 ± 26 | | 462.6 ± 20 | 472.0 ± 25 | 463.4 ± 26 | 467.8 ± 16 | 472.6 ± 19 | 468.6 ± 20 |
| Lung Weight (mg) | 180.0 ± 15 | | 185.4 ± 23 | 174.6 ± 25 | 174.6 ± 6 | 171.0 ± 17 | 185.4 ± 18 | 171.0 ± 15 |
| Heart Weight (mg) | 175.0 ± 23 | | 169.8 ± 15 | 180.3 ± 28 | 166.3 ± 17 | 171.5 ± 15 | 173.3 ± 26 | 182.0 ± 21 |
| Liver Weight (g) | 1.8 ± 0.23 | | 1.8 ± 0.22 | 1.8 ± 0.18 | 1.8 ± 0.25 | 1.7 ± 0.17 | 1.9 ± 0.15 | 1.7 ± 0.3 |
| Kidney Weight (mg) | 440.0 ± 62 | | 422.4 ± 30 | 421.3 ± 41 | 453.3 ± 20 | 465.1 ± 32 | 453.2 ± 31 | 449.7 ± 22 |
| | | Female CD-1 Mice (N=5) | | | | | | |
| Body Weight (g) | 26.0 ± 1.5 | | 27.0 ± 2.8 | 25.7 ± 2.8 | 26.3 ± 1.7 | 26.3 ± 2.3 | 26.7 ± 2.5 | 26.5 ± 2.1 |
| Brain Weight (mg) | 460.0 ± 20 | | 469.2 ± 28 | 433.4 ± 17 | 446.2 ± 30 | 461.1 ± 17 | 473.8 ± 16 | 455.4 ± 17 |
| Lung Weight (mg) | 170.0 ± 21 | | 176.8 ± 25 | 161.5 ± 20 | 173.4 ± 25 | 178.5 ± 23 | 161.5 ± 30 | 173.4 ± 16 |
| Heart Weight (mg) | 150.0 ± 20 | | 156.0 ± 25 | 154.5 ± 27 | 157.5 ± 29 | 144.0 ± 30 | 148.5 ± 29 | 145.5 ± 19 |
| Liver Weight (g) | 1.3 ± 0.11 | | 1.3 ± 0.29 | 1.3 ± 0.26 | 1.3 ± 0.15 | 1.2 ± 0.16 | 1.3 ± 0.23 | 1.3 ± 0.18 |
| Kidney Weight (mg) | 280.0 ± 33 | | 282.8 ± 55 | 282.8 ± 28 | 280.0 ± 51 | 294.0 ± 27 | 294.0 ± 37 | 282.2 ± 53 |

Supplementary Table 7: Percent change in OPA 50% killing dilution of planktonic *S. pneumoniae* for LEPS(20V):PncO protein dose escalation


| | LEPS(20V):PncO OPA Titer Percent Change | | | | | |
|----------|---|-------------|--|--|--|--|
| Serotype | 34 → 68 µg | 68 → 136 μg | | | | |
| 1 | 71% | -8% | | | | |
| 2 | 24% | 26% | | | | |
| 3 | 21% | -3% | | | | |
| 4 | 28% | -4% | | | | |
| 5 | 39% | -16% | | | | |
| 6A | 35% | -10% | | | | |
| 6B | 32% | -12% | | | | |
| 7F | 37% | -3% | | | | |
| 8 | 24% | 18% | | | | |
| 9N | 17% | 14% | | | | |
| 9V | 11% | 17% | | | | |
| 12F | 18% | 16% | | | | |
| 14 | 23% | -7% | | | | |
| 17F | 10% | -10% | | | | |
| 18C | 33% | -13% | | | | |
| 19A | 35% | -8% | | | | |
| 19F | 12% | -11% | | | | |
| 20 | 20% | 0% | | | | |
| 22F | 35% | -7% | | | | |
| 23F | 20% | 9% | | | | |

Supplementary Table 8: Percent change in antibody titer for LEPS(20V):PncO protein dose escalation


| | LEPS(20V):PncO A | Antibody Titer Percent Change |
|----------|------------------|-------------------------------|
| Serotype | 34 → 68 µg | 68 → 136 μg |
| PncO | 34% | 49% |
| 1 | 106% | -12% |
| 2 | 38% | 35% |
| 3 | 70% | -69% |
| 4 | -42% | 5% |
| 5 | 119% | -57% |
| 6A | 97% | -42% |
| 6B | 76% | -43% |
| 7F | 66% | -40% |
| 8 | 19% | 17% |
| 9N | -1% | -7% |
| 9V | 24% | -37% |
| 12F | 0% | -20% |
| 14 | 47% | 0% |
| 17F | 33% | -52% |
| 18C | 87% | -21% |
| 19A | 85% | -25% |
| 19F | -20% | 9% |
| 20 | 1% | -21% |
| 22F | -6% | -15% |
| 23F | 80% | -14% |



Supplementary Figure 1: Correlation between immunosorbent assay results and bacterial homology with GlpO. Dotted lines and error bars represent the 95% confidence interval of four technical replicates.



Supplementary Figure 2: GlpO dose escalation antibody titers. Concentration of protein (black) and CPS (blue) antibodies in mice vaccinated with 34 (a), 68 (b), or 136 (c) µg of protein in LEPS(20V):GlpO formulation. Error bars represent the 95% confidence interval of four biological replicates.



Supplementary Figure 3: GlpO+PncO dose escalation antibody titers. Concentration of protein (black) and CPS (blue) antibodies in mice vaccinated with 34 (a), 68 (b), 136 (c), or 272 (d) µg of total protein in LEPS(20V):GlpO+PncO formulation. Error bars represent the 95% confidence interval of four biological replicates.